InvestorsHub Logo
Followers 63
Posts 7611
Boards Moderated 1
Alias Born 01/02/2003

Re: lizzy241 post# 375722

Wednesday, 04/27/2022 7:07:33 PM

Wednesday, April 27, 2022 7:07:33 PM

Post# of 430303
I agree Lizzy....Assuming we see no growth in US sales of Vascepa in Q2, Amarin should IMHO cease marketing expenses in the US and do the R&D for a combo product for the US...and, in the meantime, concentrate on Vascepa for Europe.

The combo product will have appeal for the many millions of patients already on a statin.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News